BD announces assay for immune assessment of COVID-19 patients now available in Europe

October 16, 2020  –  BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) received CE mark and announced European availability of a product for assessing immune function in COVID-19 patients.

The BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes has been CE marked with expanded clinical application for the identification and enumeration of T-cell subtypes in COVID-19 patients.

According to BD, data from the first global wave of COVID-19 has shown that patients typically exhibit a remarkable decrease of CD4 and/or CD8 lymphocyte counts with increasing disease severity.

The BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes leverages time-tested technology for immune assessment and enables clinicians to go beyond the complete blood count (CBC) to better understand the underlying mechanisms for severity in COVID-19 patients, especially those with co-morbidities. This test has been used for more than a decade to assess immune function in HIV patients and may now also help clinicians better understand COVID-19 patient immune response, and when used in conjunction with clinical findings and laboratory testing, inform patient treatment plans and prioritize precious resources.

The BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes is used in conjunction with the BD FACSLyric and BD FACSCanto II Clinical Flow Cytometers and the BD FACSLyric/BD FACSDuet Sample-to-Answer Solution, which enables automated processing of samples, removing any unnecessary exposure to lab personnel. 

Learn More